发生于B细胞慢性淋巴细胞白血病的氟达拉滨相关自身免疫性溶血性贫血。

Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.

作者信息

Nishida Hiroko, Murase Tadashi, Ueno Hironori, Park Jae Wong, Yano Takahiro, Ikeda Yasuo

出版信息

Leuk Res. 2006 Dec;30(12):1589-90. doi: 10.1016/j.leukres.2006.02.011. Epub 2006 Mar 20.

DOI:10.1016/j.leukres.2006.02.011

Abstract

Autoimmune phenomena are reported to occur frequently in B-cell chronic leukemia (B-CLL). Fludarabine, one of the most effective chemotherapeutic agents for CLL, may increase the risk of these phenomena and may be life-threatening. Here we present a case of an 80-year-old man with B-CLL who developed autoimmune hemolytic anemia (AIHA), associated with one cycle of fludarabine treatment, and who was successfully treated with rituximab and prednisolone.

摘要

据报道，自身免疫现象在B细胞慢性淋巴细胞白血病（B-CLL）中频繁发生。氟达拉滨是治疗CLL最有效的化疗药物之一，可能会增加这些现象的风险，甚至可能危及生命。在此，我们报告一例80岁的B-CLL男性患者，在接受一个周期的氟达拉滨治疗后发生了自身免疫性溶血性贫血（AIHA），并通过利妥昔单抗和泼尼松龙成功治愈。